Dirk Zboralski

Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using ¹⁷⁷Lu-FAP-2286: First-in-Humans Results

Richard P. Baum, Christiane Schuchardt, Aviral Singh et al. · Journal of Nuclear Medicine · 2021 · 327 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy

Dirk Zboralski, Aileen Hoehne, Anne Bredenbeck et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2022 · 254 citations · Full text

Medicine, Nuclear Medicine, Radiology +17

The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization

Julia Hoellenriegel, Dirk Zboralski, Christian Maasch et al. · Blood · 2013 · 236 citations · Full text

Medicine, Cell Biology, Oncology +8

Increasing Tumor-Infiltrating T Cells through Inhibition of CXCL12 with NOX-A12 Synergizes with PD-1 Blockade

Dirk Zboralski, Kai Hoehlig, Dirk Eulberg et al. · Cancer Immunology Research · 2017 · 165 citations

Life Sciences, Immunology, Oncology +17

The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys

Frank Schwoebel, Lucas T. van Eijk, Dirk Zboralski et al. · Blood · 2013 · 154 citations

Medicine, Hematology, Immunology +15